Oncology Evolved

with off-the-shelf cellular therapies for cancer

PIPELINE

PRE-CLINICAL

CLINICAL

AML

WU-NK-101

Head & Neck Cancer

WU-NK-101 + Cetuximab

Melanoma

WU-NK-101 (post-checkpoint inhibitor)

Solid Tumors

WU-NK-201

T-ALL

WU-CART-007

LATEST NEWS

Wugen Presents New Preclinical Data from Novel Memory Natural Killer (NK) Platform at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

Wugen’s proprietary platform employs a GMP-grade, feeder cell-free manufacturing process to produce commercially scalable, off-the-shelf, non-engineered memory natural killer (NK)…

Read more
Wugen to Present Virtually at the Upcoming Jefferies London Healthcare Conference

ST. LOUIS, MO and SAN DIEGO, CA, November 10, 2021 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline…

Read more
Wugen Announces Data Presentation at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

ST. LOUIS, MO and SAN DIEGO, CA, November 9, 2021 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline…

Read more
OPTIMIZED BY EVOLUTION

Wugen is developing off-the-shelf cellular therapies for cancer

Radio Button Off
About Wugen

Wugen is a clinical-stage biotechnology company

Flask
Science

Cellular therapies originating from healthy donors

People
Careers

Come join our growing teams in San Diego and St. Louis